Do human lymphocyte antigens play a role in the clinical antimelanoma activity of ipilimumab?

Immunotherapy

Volumn 3, Issue 5, 2011, Pages 595-599

  Brown, Michael P ^a  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

autologous graft versus host disease; CTLA 4; ipilimumab; melanoma; MHC

Indexed keywords

GLYCOPROTEIN GP 100; HLA A2 ANTIGEN; HLA ANTIGEN; IPILIMUMAB;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL TOXICITY; HUMAN; LIVER TOXICITY; MELANOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RETROSPECTIVE STUDY; SKIN BIOPSY; SKIN TOXICITY;

EID: 79955926221     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/imt.11.23     Document Type: Article

References (22)

1. Hodi FS, O'Day SJ, McDermott DF et al.: Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723 (2010).
2. Wolchok JD, Weber JS, Hamid O et al.: Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials. Cancer Immun. 10, 9-14 (2010).
3. Schmidt H, Hamid O, Nissan A et al.: Identification of tumor biopsy markers as potential predictors of ipilimumab clinical activity in patients with advanced melanoma. Eur. J. Cancer 45(Suppl.), 577a (2009).
4. O'Day SJ, Maio M, Chiarion-Sileni V et al.: Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm Phase II study. Ann. Oncol. 21, 1712-1717 (2010).
5. Wolchok JD, Neyns B, Linette G et al.: Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, Phase 2, dose-ranging study. Lancet Oncol. 11, 155-164 (2010).
6. Weber J, Thompson JA, Hamid O et al.: A randomized, double-blind, placebo-controlled, Phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin. Cancer Res. 15, 5591-5598 (2009).
7. van Elsas A, Sutmuller RP, Hurwitz AA et al.: Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J. Exp. Med. 194, 481-489 (2001). (Pubitemid 32835043)
8. Barrow C, Browning J, MacGregor D et al.: Tumor antigen expression in melanoma varies according to antigen and stage. Clin. Cancer Res. 12, 764-771 (2006). (Pubitemid 43259856)
9. Rosenberg SA: A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 10, 281-287 (1999). (Pubitemid 29165283)
10. Lee PP, Yee C, Savage PA et al.: Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat. Med. 5, 677-685 (1999). (Pubitemid 29289432)
11. Klein O, Ebert LM, Nicholaou T et al.: Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4. Clin. Cancer Res. 15, 2507-2513 (2009).
12. Phan GQ, Attia P, Steinberg SM, White DE, Rosenberg SA: Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J. Clin. Oncol. 19, 3477-3482 (2001). (Pubitemid 32730084)
13. Hess AD: Modulation of graft-versus-host disease: role of regulatory T lymphocytes. Biol. Blood Marrow Transplant. 12, 13-21 (2006). (Pubitemid 43034107)
14. Holmberg L, Kikuchi K, Gooley TA et al.: Gastrointestinal graft-versus-host disease in recipients of autologous hematopoietic stem cells: incidence, risk factors, and outcome. Biol. Blood Marrow Transplant 12, 226-234 (2006). (Pubitemid 43138017)
15. Oble DA, Mino-Kenudson M, Goldsmith J et al.: a-CTLA-4 mAb-associated panenteritis: a histologic and immunohistochemical analysis. Am. J. Surg. Pathol. 32, 1130-1137 (2008).
16. Berman D, Parker SM, Siegel J et al.: Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immun. 10, 11 (2010).
17. + cytotoxic T cell responses in primary biliary cirrhosis: T cell activation is augmented by immune complexes cross-presented by dendritic cells. J. Exp. Med. 195, 113-123 (2002). (Pubitemid 34074501)
18. Agarwal K, Jones DE, Daly AK et al.: CTLA-4 gene polymorphism confers susceptibility to primary biliary cirrhosis. J. Hepatol. 32, 538-541 (2000). (Pubitemid 30180371)
19. Arbuckle MR, McClain MT, Rubertone MV et al.: Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N. Engl. J. Med. 349, 1526-1533 (2003). (Pubitemid 37255038)
20. + regulatory T cells abrogates their function in vivo. J. Immunol. 177, 4376-4383 (2006). (Pubitemid 44469766)
21. Stefanova I, Dorfman JR, Germain RN: Self-recognition promotes the foreign antigen sensitivity of naive T lymphocytes. Nature 420, 429-434 (2002). (Pubitemid 35415655)
22. + T cells against NY-ESO-1. N. Engl. J. Med. 358, 2698-2703 (2008). (Pubitemid 351860862)